Trial Profile
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Glycemic Effect of Rimonabant Added to Metformin in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2017
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms TOCCATA
- Sponsors Sanofi
- 17 Jun 2009 Actual patient number (403) added as reported by ClinicalTrials.gov.
- 27 Nov 2008 Status changed from active, no longer recruiting to discontinued.
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.